MP
TCRT icon

MSD Partners’s Alaunos Therapeutics TCRT Stock Holding History

MSD Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,505
Closed -$998K – 63
2023
Q3 		$998K Hold
50,505
– – 0.08% 32
2023
Q2 		$3.86M Hold
50,505
– – 0.36% 15
2023
Q1 		$4.77M Hold
50,505
– – 0.39% 14
2022
Q4 		$4.92M Hold
50,505
– – 0.48% 14
2022
Q3 		$13M Hold
50,505
– – 1.05% 8
2022
Q2 		$9.39M Hold
50,505
– – 0.58% 14
2022
Q1 		$4.94M Sell
50,505
-101,010
-67% -$13M 0.27% 27
2021
Q4 		$24.8M Buy
151,515
+101,010
+200% +$22.2M 0.27% 32
2021
Q3 		$13.8M Buy
+50,505
New +$15.4M 0.42% 24

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MSD Partners's TCRT Position: Q4 2024 in Review

MSD Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2024, closing a stake of 101,010 shares — an estimated $325K sold.

MSD Partners first reported a position in TCRT in Q2 2013 and held it in 46 quarters. The position peaked at $71.5M in Q4 2019. 30 funds tracked by Wall St. Rank hold TCRT as of Q4 2024.

  • MSD Partners reported no remaining Alaunos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MSD Partners sold 101,010 Alaunos Therapeutics shares in Q4 2024, an estimated $325K.
  • MSD Partners first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 46 quarters.
  • MSD Partners's Alaunos Therapeutics position peaked at $71.5M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2024.

Based on MSD Partners's 13F filing for Q4 2024, filed 14 Feb 2025.